Use of real world data to improve drug coverage decisions in China

doi:10.1136/bmj-2021-068911

. 2023 Jun 15:381:e068911.

doi: 10.1136/bmj-2021-068911.

Use of real world data to improve drug coverage decisions in China

Wen Wang^{1

2

3}, Jing Tan^{1

2

3}, Jing Wu⁴, Shiyao Huang^{1

2

3}, Yunxiang Huang^{1

2

3}, Feng Xie⁵, Xin Sun^{1

2

3}

Affiliations

¹ Chinese Evidence-based Medicine Centre, and National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China.
³ Sichuan Center of Technology Innovation for Real World Data, Chengdu, China.
⁴ School of Pharmacology Science and Technology, Tianjin University, Tianjin, China.
⁵ Department of Clinical Epidemiology and Biostatistics, University of Macmaster, Hamilton, Canada.

PMID: 37321633
PMCID: PMC10266438
DOI: 10.1136/bmj-2021-068911

Use of real world data to improve drug coverage decisions in China

Wen Wang et al. BMJ. 2023.

. 2023 Jun 15:381:e068911.

doi: 10.1136/bmj-2021-068911.

Authors

Wen Wang^{1

2

3}, Jing Tan^{1

2

3}, Jing Wu⁴, Shiyao Huang^{1

2

3}, Yunxiang Huang^{1

2

3}, Feng Xie⁵, Xin Sun^{1

2

3}

Affiliations

¹ Chinese Evidence-based Medicine Centre, and National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China.
³ Sichuan Center of Technology Innovation for Real World Data, Chengdu, China.
⁴ School of Pharmacology Science and Technology, Tianjin University, Tianjin, China.
⁵ Department of Clinical Epidemiology and Biostatistics, University of Macmaster, Hamilton, Canada.

PMID: 37321633
PMCID: PMC10266438
DOI: 10.1136/bmj-2021-068911

Abstract

Wen Wang and colleagues discuss the rationale and propose a framework for using real world evidence to support coverage decisions in Chinese setting

PubMed Disclaimer

Conflict of interest statement

Competing interests We have read and understood BMJ policy on declaration of interests and declare that the study was supported by the National Key R&D Program of China (Grant No 2017YFC1700406 and 2017YFC1700400), the National Natural Science Foundation of China (Grant No 82225049, 72104155), China Medical Broad (Grant No CMB 19-324), and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant No ZYYC08003). These funders had no role in the study design, collection, analysis, or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

Cited by

Applications of Artificial Intelligence in Drug Repurposing.
Wan Z, Sun X, Li Y, Chu T, Hao X, Cao Y, Zhang P. Wan Z, et al. Adv Sci (Weinh). 2025 Apr;12(14):e2411325. doi: 10.1002/advs.202411325. Epub 2025 Mar 6. Adv Sci (Weinh). 2025. PMID: 40047357 Free PMC article. Review.
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.
Sun F, Bedenkov A, Liu BC, Yang J, Xu JF, Ji L, Zhou M, Zhang S, Li X, Song Y, Chen P, Moreno C. Sun F, et al. Pharmaceut Med. 2024 May;38(3):157-166. doi: 10.1007/s40290-024-00520-3. Epub 2024 Apr 4. Pharmaceut Med. 2024. PMID: 38573457 Free PMC article.
Evaluating the agreement between sensitivity and primary analyses in observational studies using routinely collected healthcare data: a meta-epidemiology study.
Xu J, Wang Y, He Q, Xie S, Feng S, Wang X, Wang W, Sun X. Xu J, et al. BMC Med. 2025 Jul 1;23(1):393. doi: 10.1186/s12916-025-04199-4. BMC Med. 2025. PMID: 40598156 Free PMC article.
Formulation of a CITE metric for evaluating the clinical implications of medical studies and their originating hospitals in China.
Jianchao G, Xiaoyuan C, Chenyan G. Jianchao G, et al. Health Care Sci. 2024 Aug 6;3(4):264-273. doi: 10.1002/hcs2.108. eCollection 2024 Aug. Health Care Sci. 2024. PMID: 39220428 Free PMC article.
Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.
Chen X, Ou S, Luo J, He Z, Jiang Q. Chen X, et al. Front Pharmacol. 2024 Jun 4;15:1374549. doi: 10.3389/fphar.2024.1374549. eCollection 2024. Front Pharmacol. 2024. PMID: 38898925 Free PMC article. Review.

References

1. Chinese State Council. 74 drugs to be added to national insurance list. 2021. http://english.www.gov.cn/statecouncil/ministries/202112/07/content_WS61...
1. Technology Development Center of Chinese Pharmaceutical Association . Blue book on progress and achievement of medical insurance reform in China. CPA, 2021.
1. Chinese State Council. Over 60 rare-disease drugs approved for Chinese market. 2021. https://english.www.gov.cn/statecouncil/ministries/202112/19/content_WS6...
1. Tang Z, Guo J, Tang J, Ying X. Analysis on the current situation of listed innovative drugs in China from 2017 to 2020. World Clinical Drugs 2022;43:294-9.
1. Zhou T, Sheng Y, Guan H. Cost-effectiveness of vedolizumab in the treatment of moderate-to-severe Crohn’s disease in China. Adv Ther 2021;38:4233-45. 10.1007/s12325-021-01806-7 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Chinese State Council. 74 drugs to be added to national insurance list. 2021. http://english.www.gov.cn/statecouncil/ministries/202112/07/content_WS61...

[2] Chinese State Council. 74 drugs to be added to national insurance list. 2021. http://english.www.gov.cn/statecouncil/ministries/202112/07/content_WS61...

[3] Technology Development Center of Chinese Pharmaceutical Association . Blue book on progress and achievement of medical insurance reform in China. CPA, 2021.

[4] Technology Development Center of Chinese Pharmaceutical Association . Blue book on progress and achievement of medical insurance reform in China. CPA, 2021.

[5] Chinese State Council. Over 60 rare-disease drugs approved for Chinese market. 2021. https://english.www.gov.cn/statecouncil/ministries/202112/19/content_WS6...

[6] Chinese State Council. Over 60 rare-disease drugs approved for Chinese market. 2021. https://english.www.gov.cn/statecouncil/ministries/202112/19/content_WS6...

[7] Tang Z, Guo J, Tang J, Ying X. Analysis on the current situation of listed innovative drugs in China from 2017 to 2020. World Clinical Drugs 2022;43:294-9.

[8] Tang Z, Guo J, Tang J, Ying X. Analysis on the current situation of listed innovative drugs in China from 2017 to 2020. World Clinical Drugs 2022;43:294-9.

[9] Zhou T, Sheng Y, Guan H. Cost-effectiveness of vedolizumab in the treatment of moderate-to-severe Crohn’s disease in China. Adv Ther 2021;38:4233-45. 10.1007/s12325-021-01806-7 - DOI - PMC - PubMed

[10] Zhou T, Sheng Y, Guan H. Cost-effectiveness of vedolizumab in the treatment of moderate-to-severe Crohn’s disease in China. Adv Ther 2021;38:4233-45. 10.1007/s12325-021-01806-7 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Use of real world data to improve drug coverage decisions in China

Affiliations

Use of real world data to improve drug coverage decisions in China

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Medical